Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.63 |
| ▸ | HRH1 | P35367 | 2/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2705400 | 0.98 | HRH3 (0.61) | HRH3HRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18318183 | 0.95 | HRH3 (0.58) | HRH3HRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8271830 | 0.89 | HRH3 (0.55) | HRH3HRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13636042 | 0.89 | HRH3 (0.55) | HRH3HRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31632587 | 0.89 | HRH3 (0.55) | HRH3HRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22138868 | 0.88 | HRH3 (0.71) | HRH3HRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5024491 | 0.88 | HRH3 (0.71) | HRH3HRH1SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL4233307 | 0.85 | EPHX2 (0.50) | HRH3HRH1KCNH2EPHX2 | |
| SCHEMBL21130985 | 0.85 | HRH3 (0.67) | HRH3EPHX2 | |
| SCHEMBL247758 | 0.85 | HRH3 (0.71) | HRH3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | claimed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | claimed |
| EP-3221307-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2017-09-27 | — | — | EP | claimed |
| WO-2016079760-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-26 | — | — | WO | claimed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-3571203-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4144735-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | DIGMBIO. INC. (KR) | 2023-01-26 | — | — | US | disclosed |
| CN-115210225-A | Substituted aminoquinolones as immuno-activated DGKALPHA inhibitors | 拜耳公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-1030836-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LTD (GB) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002012190-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| US-6187924-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TUMOR NECROSIS FACTOR-ALPHA-MEDIATED DISEASES | DARWIN DISCOVERY, LTD. (GB) | 2001-02-13 | — | — | US | disclosed |
| EP-1030836-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999024399-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | HRH3 437/4885HRH1 326/4885SLC6A2 4689/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | HRH3 1000/4885HRH1 1109/4885SLC6A2 4053/4885 |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | RET, BRAF, ROR1 | HRH3 1469/4885HRH1 1202/4885SLC6A2 4195/4885 |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | FAAH, FAAH2, EPHX2 | HRH3 230/4885HRH1 169/4885SLC6A2 2175/4885 |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | PIK3CA, PIK3R5, PIK3CD | HRH3 4044/4885HRH1 3298/4885SLC6A2 4708/4885 |
| US-20230027362-A1 | ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT | PARP1, PARP2, PARP11 | HRH3 3708/4885HRH1 1819/4885SLC6A2 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.